Antiphospholipid syndrome matters because it can turn an otherwise invisible immune abnormality into a stroke, pulmonary embolism, recurrent miscarriage, or placental complication. For patients, the diagnosis often arrives after a frightening clot or pregnancy loss. For clinicians, the challenge is distinguishing a transient positive antibody test from a durable, treatment-changing thrombotic risk.

What APS is, and why rheumatologists care

Antiphospholipid syndrome, or APS, is an acquired autoimmune thrombophilia. The immune system produces antibodies that interact with phospholipid-binding proteins, especially beta-2 glycoprotein I and prothrombin. Those antibodies do not simply “thicken” blood. They activate endothelial cells, platelets, monocytes, and complement pathways, shifting the vasculature toward clot formation.

Rheumatologists care because APS sits at the intersection of hematology, obstetrics, neurology, nephrology, and systemic autoimmunity. It may occur alone, but it commonly overlaps with systemic lupus erythematosus. In lupus, persistent lupus anticoagulant or high-titer anticardiolipin and anti-beta-2 glycoprotein I antibodies meaningfully change risk counseling, medication choices, and pregnancy planning.

Diagnosis requires more than one abnormal lab

The 2023 ACR/EULAR classification criteria sharpened how researchers identify APS by requiring at least one clinical criterion and one laboratory criterion, weighted by risk. Classification criteria are not a substitute for bedside diagnosis, but they reflect an important principle: APS is not diagnosed from a single antibody result in isolation.

Clinically relevant events include venous thrombosis, arterial thrombosis, and specific obstetric morbidity such as otherwise unexplained fetal death, early severe preeclampsia with placental insufficiency, or recurrent early pregnancy losses. Laboratory confirmation generally requires persistence, meaning positive testing on two occasions at least 12 weeks apart.

The core antibody panel

Standard testing focuses on three groups:

• lupus anticoagulant, a functional coagulation assay and the strongest single laboratory predictor of thrombosis;
• anticardiolipin IgG or IgM antibodies, with medium or high titers carrying more significance;
• anti-beta-2 glycoprotein I IgG or IgM antibodies, particularly when persistent and high titer.

The highest-risk profile is “triple positivity,” where all three tests are persistently positive. Low-titer, isolated IgM positivity, especially after infection or in older adults, deserves careful interpretation rather than automatic labeling.

How APS causes clots and pregnancy complications

APS can cause deep vein thrombosis, pulmonary embolism, ischemic stroke, myocardial infarction, renal microangiopathy, livedo reticularis, and thrombocytopenia. A practical example: a 38-year-old woman with lupus develops an unprovoked calf deep vein thrombosis. Her lupus anticoagulant is positive during hospitalization. If repeat testing 12 weeks later remains positive and anticardiolipin IgG is high, the diagnosis carries very different implications than a provoked clot after surgery.

In pregnancy, APS is not merely a clotting disorder in miniature vessels. Antiphospholipid antibodies can interfere with trophoblast function, placental development, and complement regulation. That biology explains why APS is linked to fetal loss, fetal growth restriction, preeclampsia, and premature delivery, not only maternal thrombosis.

Treatment logic: intensity follows the phenotype

For thrombotic APS, the central treatment question is not whether the antibody exists, but whether the patient has had a qualifying clot and what type. Long-term vitamin K antagonist therapy, usually warfarin, remains the evidence-supported standard after unprovoked venous or arterial APS events. The target international normalized ratio, or INR, is commonly 2.0 to 3.0 for venous disease, with individualized escalation or antiplatelet therapy considered for arterial recurrence.

Direct oral anticoagulants are a common point of confusion. They are effective for many ordinary venous clots, but APS is not ordinary thrombosis. The TRAPS trial found excess recurrent events, especially arterial events, with rivaroxaban in triple-positive APS compared with warfarin. EULAR guidance therefore discourages rivaroxaban in high-risk APS, particularly triple-positive or arterial disease.

Obstetric APS

For obstetric APS, treatment aims to support placental function and prevent thrombosis without increasing bleeding unnecessarily. Guideline-based care commonly uses low-dose aspirin plus prophylactic heparin during pregnancy for patients meeting obstetric APS criteria, with postpartum anticoagulation considered because clot risk rises after delivery. Hydroxychloroquine is often continued in lupus because it reduces lupus activity and may favorably influence thrombotic risk.

Misconceptions that change care

One misconception is that every positive antiphospholipid antibody requires anticoagulation. It does not. An asymptomatic patient with a low-risk antibody profile may need cardiovascular risk reduction, avoidance of estrogen-containing therapy when appropriate, and monitoring in context, not lifelong warfarin. Conversely, a patient with prior arterial thrombosis and triple positivity should not be reassured by a normal platelet count or a temporarily negative test.

Another misconception is that APS explains all miscarriages. Pregnancy loss is common and has many causes. APS evaluation is most useful when the pattern fits established criteria or when lupus and other autoimmune features raise the pretest probability. Over-testing low-probability situations can create anxiety and ambiguous results.

Risk management beyond anticoagulation

Clinical reasoning in APS extends beyond choosing a drug. Smoking cessation, blood pressure control, lipid management, diabetes care, mobility during travel or hospitalization, and avoidance of unnecessary estrogen exposure are not cosmetic details; they lower the background triggers that can convert antibody-mediated risk into an event.

In lupus-associated APS, disease control also matters. Active systemic inflammation, nephrotic-range protein loss, complement activation, and high glucocorticoid exposure can amplify thrombosis risk. That is why rheumatology follow-up often integrates lupus activity assessment, kidney surveillance, medication safety, and coordination with hematology or maternal-fetal medicine.

Where the evidence stands

The evidence supports persistent antibody confirmation, warfarin for high-risk thrombotic APS, and aspirin plus heparin for defined obstetric APS. Uncertainty remains around refractory disease, low-risk profiles, and newer targeted therapies overall.